2.370USD-2.87%Mkt Cap: 72.26M USDP/E: —Last update: 2026-06-01
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious dise…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap72.26M USD
Enterprise Value-41.37M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-45.54M USD
Revenue/Share—
Last Price2.370 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees87
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINCA98400H1029
Valuation
P/E (Trailing)—
P/E (Forward)18.62
PEG—
EV/EBITDA0.88
EV/Revenue—
P/S—
P/B0.53
EPS (TTM)-1.31
EPS (Forward)0.13
52W Range
2.09018% of range3.610
52W High3.610 USD
52W Low2.090 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-32.45%
ROA-30.34%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-39.92M USD
CapEx (TTM)289.00K USD
FCF Margin—
FCF Yield-42.38%
Net Debt-115.46M USD
Net Debt/EBITDA2.47
Balance Sheet
Debt/Equity—
Current Ratio39.03
Quick Ratio38.60
Book Value/Sh4.603 USD
Cash/Share3.787 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJul 15, 2021
Pay DateJul 23, 2021
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.30.49M
Float22.84M
Insiders24.33%
Institutions6.84%
Short Interest
Short Ratio7.2d
Short % Float0.71%
Short % Out.0.60%
Shares Short184.01K
Short (prev mo.)148.53K
Technical
SMA 502.434 (-2.6%)
SMA 2002.534 (-6.5%)
Beta0.86
S&P 52W Chg27.70%
Avg Vol (30d)25.25K
Avg Vol (10d)24.00K
Technical Indicators
RSI (14)47.7
MACD-0.0077
MACD Signal-0.0016
MACD Hist.-0.0061
BB Upper2.580 USD
BB Middle2.471 USD
BB Lower2.363 USD
BB Width8.76%
ATR (14)0.0649 USD
Vol Ratio (20d)1.74x